Business Context and Reporting Period
This Form 10-Q covers DAXOR CORP for the quarter and six months ended June 30, 1997. The company operates clinical laboratories, a blood bank, and a semen bank, while developing a Blood Volume Analyzer (BVA-100). Operations are significantly impacted by ongoing litigation with the New York State Department of Health regarding licensing and a federal RICO/Antitrust suit against the New York Blood Center.
Key Financial Metrics
| Metric | Six Months Ended June 30, 1997 | Six Months Ended June 30, 1996 |
|---|---|---|
| Total Revenues | $1,572,045 | $1,458,856 |
| Operating Revenues | $295,015 | $431,565 |
| Dividend Income | $1,070,612 | $1,042,892 |
| Net Income | $329,517 | ($127,060) |
| Net Income Per Share | $0.07 | ($0.03) |
| Cash from Operating Activities | $270,200 | $199,685 |
| Total Assets | $35,730,953 | $37,288,804 |
| Marketable Securities (Fair Value) | $34,262,628 | $35,574,526 |
| Loans Payable | $3,524,792 | $1,636,067 |
| Cash and Cash Equivalents | $69,270 | $123,115 |
Material Changes vs. Prior Period
- Revenue Composition: While total revenue increased slightly, operating revenues from laboratory services declined by approximately 32% ($136,550 decrease) due to the revocation of licenses and legal restrictions. This decline was offset by gains on the sale of securities and stable dividend income.
- Profitability: The company returned to profitability with a net income of $329,517, compared to a net loss of $127,060 in the prior year period. This turnaround is primarily driven by investment gains rather than core operations.
- Liquidity and Debt: Cash on hand decreased by $53,845. Loans payable increased significantly by $1,888,725, driven by an $800,000 bank loan and increased margin debt with brokers to purchase investments.
- Dividends: The company paid a dividend of $0.50 per share ($2,353,755 total) in May 1997, a significant cash outflow not present in the comparable prior period.
Outlook, Risks, and Management Commentary
- Legal Risks: The New York State Court of Appeals reversed a lower court decision, ruling Daxor had no property interest in its clinical laboratory and sperm bank licenses. This decision threatens the company's ability to provide blood and semen banking services in New York State. The company is unable to accept new clients but maintains current ones.
- Product Development: The Blood Volume Analyzer (BVA-100) is awaiting FDA approval and has not yet generated revenue. Manufacturing agreements are in place with Oxford N.M.G. and Wellport INC.
- Contingencies: Daxor is pursuing a $100 million federal RICO/Antitrust suit against the New York Health Department and the New York Blood Center, alleging conspiracy and antitrust violations. Management states a victory could recoup financial damages.
- Liquidity: Management asserts adequate resources to sustain current operations and marketing for the BVA-100. However, expanding blood banking operations nationwide would require additional capital.
Investor Verification Checklist
- Verify the current status of the New York State Court of Appeals ruling and any pending motions for re-argument regarding laboratory licenses.
- Confirm the timeline for FDA approval of the Blood Volume Analyzer (BVA-100) and potential revenue impact.
- Assess the progress and likelihood of success in the $100 million federal RICO/Antitrust lawsuit.
- Review the composition of the investment portfolio and the sustainability of dividend income as a primary revenue source.
- Monitor the level of margin debt and loans payable secured by marketable securities.